Arndt Vogel, Head of the Center for Personalized Medicine, MHH at Medical University of Hanover, shared a post on LinkedIn:
“Survival and Safety of Tinengotinib in Pooled Patients with Advanced FGFR inhibitor Refractory/Relapsed CCA.
- No difference in outcome for FGRF naive vs pretreated pts with FGFR2 fusions.
- Great option for sequential FGFRi in BTC, looking forward to FIRST-308.”
You can also read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
ESMO 2025 Day 3 Highlights Not to Miss
ESMO 2025 Day 4 Highlights Not to Miss
